AstraZeneca's Breztri Aerosphere Approved for Asthma Treatment

AstraZeneca's fixed-dose triple-combination therapy Breztri Aerosphere has been approved in the US for the maintenance treatment of asthma in adult and paediatric patients 12 years of age and older. Breztri is a single-inhaler that combines the efficacy of corticosteroid/long-acting beta2-agonist medicines with a long-acting muscarinic antagonist, LAMA. Breztri was approved in the US in 2020 to treat adults with chronic obstructive pulmonary disease, COPD, and was prescribed to more than 6.8 million patients globally in 2025. The approval by the US Food and Drug Administration was based on efficacy and safety data from the Phase III KALOS and LOGOS trials investigating Breztri in a broad population consisting of patients with asthma, with or without a recent asthma exacerbation.